Symphogen leads the field of mAb mixtures and is developing a variety of products for multiple infectious disease and hematology/oncology indications, alone and in partnership. We continue to seek value-generating partnerships to leverage our internal capabilities, including relationships with large biotechnology and pharmaceutical companies with late stage development and commercialization capabilities.

Symphogen's technologies and expertise within the antibody field have been validated through its corporate partnerships with pharmaceutical companies in the US, Europe, and Japan.

Business Development Inquiries:

Jette Asboe Lassen, 
Director, Business Development 
Pederstrupvej 93 
DK-2750 Ballerup